Promising Therapy for Patients with Advanced Kidney Cancer

Share this content:

the Cancer Therapy Advisor take:

Patients with advanced papillary renal cell carcinoma and patients with hereditary leiomyomatosis and renal cell cancer, a very aggressive form of papillary renal cell carcinoma, currently have a poor prognosis and there is no standard treatment regimen for their disease.

Research led by Ramaprasad Srinivasan, MD, PhD, of the National Cancer Institute in Bethesda, MD, indicates that the combination of erlotinib and bevacizumab produced an significant increase in rate of treatment response and was associated with manageable side-effects in this group of patients.

The researchers recruited 41 patients in their phase II clinical trial and intravenously administered 10 mg of bevacizumab for each kg of the patient’s weight combined with a 150 mg daily dose of oral erlotinib. The treatment was continued until disease progression or intolerable side effects occurred. In the first group, 20 patients had been diagnosed with advanced hereditary leiomyomatosis and renal cell cancer and 21 patients in the second group had advanced sporadic non-hereditary papillary renal cell carcinoma.

Out of both groups, 19 of the patients enrolled in the trial had received at least one previous systemic therapy (eg, sunitinib) that led to disease progression. Almost all patients enrolled in the clinical trial with hereditary leiomyomatosis and renal cell cancer saw a decrease in their tumor size or remained stable without progression. 

The overall response rate was 65% and many of the response were long lasting, with some patients remaining on the study for 3 years or more. This treatment regimen shows significant promise for patients with advanced kidney cancer, particularly patients with hereditary leiomyomatosis and renal cell cancer.

Promising Therapy for Patients with Advanced Kidney Cancer
Patients with advanced papillary renal cell carcinoma currently have a poor prognosis.
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. Dr Ramaprasad Srinivasan, head of the Molecular Cancer Therapeutics Section, Urologic Oncology Branch, of the National Cancer Institute in Maryland, USA, will tell the 26th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, that the combination of bevacizumab and erlotinib produced excellent response rates with tolerable side-effects in patients with advanced papillary renal cell carcinoma (pRCC) and in patients with a highly aggressive form of pRCC called hereditary leiomyomatosis and renal cell cancer (HLRCC).
READ FULL ARTICLE From Medical News Today

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs